gpt-dict.com

SAMe for Osteoarthritis

Verdict: Weak, inconsistent evidence for osteoarthritis pain

SAMe may modestly ease osteoarthritis pain, but the best placebo-controlled evidence is null, so any benefit is unproven and it is not a reliable treatment. It is graded weak evidence and published with a warning.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The grade is held to weak (Tier C) because the methodologically strongest study, the 2009 Cochrane review of four placebo-controlled trials in 656 knee or hip osteoarthritis patients (PMID 19821403), found SAMe no better than placebo for pain (SMD -0.17, confidence interval crossing zero) and essentially no functional benefit (SMD 0.02), judging the evidence inconclusive. Both SAMe and placebo improved pain by about 2 points, pointing to a large placebo response rather than a true drug effect.

The more encouraging picture comes from weaker designs. A 2002 government-funded meta-analysis (PMID 12019049) reported reduced functional limitation but no significant pain benefit versus placebo, and head-to-head trials against nabumetone (PMID 20110025) and celecoxib (PMID 15102339, industry-supplied SAMe) found it roughly comparable with fewer side effects but slower onset. These active-comparator trials lack a placebo arm, so apparent equivalence can simply reflect a shared placebo response.

Regulators and clinics reinforce the caution. The US FDA/NCCIH note SAMe is only a dietary supplement in the US (a prescription drug in parts of Europe), and Mayo Clinic states that while many NSAID-comparison studies showed similar relief, a smaller number did not. Trials are old, small, and heterogeneous, justifying publication only with a warning.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.42
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
77%
Broadly consistent
Evidence level
E1
Cochrane high-quality SR/MA

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L5 Clinical bodiesAuthoritative stance
0.47
L11 AI re-checkIndependent read
0.50
L1 ExamineGlobal benchmark
0.70
Against Mixed Supports
▸View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.416
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標，未降階
  5. detect_disputes — 偵測到 0 個 hard + 2 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

S-Adenosylmethionine for osteoarthritis of the knee or hip
PMID: 19821403 2009 Cochrane SR n = 656
Finding: Versus placebo, SAMe produced only a small, non-significant pain effect (SMD -0.17, ~0.4 cm on a 10 cm VAS) and negligible functional change (SMD 0.02). Both SAMe and placebo improved pain by about 2 points on a 0-10 scale over 3 months. Methodological quality and reporting were poor; review judged inconclusive.
Effect size: Pain SMD -0.17 (95% CI -0.34 to 0.01); Function SMD 0.02 (95% CI -0.68 to 0.71)
View on PubMed
Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis
PMID: 12019049 2002 統合分析
Finding: Versus placebo, SAMe reduced functional limitation (effect size 0.31) but not pain significantly (effect size 0.22, based on only 2 studies). Versus NSAIDs, SAMe was comparable for pain (0.12) and function (0.025) and patients on SAMe were less likely to report adverse effects.
Government Effect size: vs placebo: function ES 0.31, pain ES 0.22 (NS); vs NSAIDs: pain ES 0.12, function ES 0.025
View on PubMed
Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Kore…
PMID: 20110025 2009 RCT (double-blind) n = 134
Finding: Both treatments significantly reduced pain from baseline (SAMe -13.0 mm, nabumetone -15.7 mm; both P<0.001) with no significant between-group difference. WOMAC and global assessments were comparable. No significant difference in pain relief or tolerability over 8 weeks.
Effect size: Between-group pain difference not significant (SAMe -13.0 mm vs nabumetone -15.7 mm)
View on PubMed
S-Adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial
PMID: 15102339 2004 RCT (double-blind) n = 61
Finding: In month 1 celecoxib produced significantly greater pain reduction (p=0.024); by month 2 there was no significant difference between treatments and equivalence was met. Both groups improved in function. SAMe has a slower onset of action but was as effective as celecoxib by 2 months.
🟠 Limited quality ⚠️ Industry-funded Effect size: Month 1 favors celecoxib (p=0.024); Month 2 equivalent (10% threshold)
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
A lab-made form of SAMe is sold as a dietary supplement in the U.S., but SAMe has been sold as a prescription drug in parts of Europe for decades. source↗
L4d TW TFDA / 衛福部
Neutral
從 1970 年代起，歐洲已廣泛使用 SAMe 來治療憂鬱症及其他生理狀況；1999 年美國則依《膳食補充劑健康與教育法》核准口服腸溶 SAMe 劑型，使消費者得於零售通路購買。 source↗
L5a NIH Office of Dietary Supplements
Cautious
L5b Mayo Clinic
Neutral
Many studies comparing the use of SAMe with nonsteroidal anti-inflammatory drugs showed that each provided similar pain relief and improvement in joint function, but SAMe produced fewer side effects. However, a smaller number of studies haven't shown the same results. source↗
L5d Harvard Health
Cautious
L5e Specialty Society (condition-mapped)
Not addressed
✓PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-osteoarthritis-INT-s-adenosylmethionine-001 繁體中文版 →